Virax Biolabs Group Limited Announces $5 Million Private Placement Virax Biolabs Group (Nasdaq: VRAX) announced a private placement to raise gross proceeds of approximately $5.0 million through the sale of 12,500,000 ordinary shares (or equivalents) and associated preferred investment options at $0.40 per share. The preferred investment options are exercisable immediately for five years from the effective date of an Initial Registration Statement. Closing is expected on or about December 4, 2025, subject to customary conditions. H.C. Wainwright is the exclusive placement agent. The company said net proceeds will be used for working capital and general corporate purposes. Virax agreed to file and seek effectiveness of a resale registration statement for the issued securities within specified timing and to repricing/extend prior Series A and B preferred options to the same terms.

#VRAX #NASDAQ Virax Biolabs Group Limited Announces $5 Million Private Placement

www.stocktitan.net/news/VRAX/virax-biolabs-...

📢 Stocks Trending NOW: #M #MRVL #CAPR #IXHL #DLTR #VRAX #RR #CRWD #PMAX #CRM

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders LONDON, Dec. 3, 2025/ PRNewswire/-- Virax Biolabs Group Limited, an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones, achievements and clinical progress while outlining its strategic priorities for 2026 in a letter to shareholders and investors. It describes Virax...

#VRAX #NASDAQ Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

www.stocktitan.net/news/VRAX/virax-biolabs-...

Revolutionary Long COVID Diagnostic: Virax Biolabs and Emory University Launch Clinical Studies for T-Cell Test Biotech firm Virax partners with Emory's ADJUST Center to validate ViraxImmune T-cell testing for long COVID diagnosis. FDA pre-submission meeting scheduled for September 2025.

#VRAX Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

www.stocktitan.net/news/VRAX/virax-biolabs-...

Virax Biolabs Gets NASDAQ Deficiency Notice: What the 180-Day Compliance Timeline Means for Investors Virax receives NASDAQ notice for sub-$1 share price with January 2026 compliance deadline. Trading continues as normal under VRAX. See compliance requirements.

#VRAX Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

www.stocktitan.net/news/VRAX/virax-biolabs-...

Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution Novel ViraxImmune™ diagnostic study launches with NHS partnership, targeting breakthrough detection methods for Long COVID, Lyme disease, and chronic fatigue syndrome.

#VRAX Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

www.stocktitan.net/news/VRAX/virax-biolabs-...

Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results Revolutionary T-Cell diagnostic technology demonstrates potential for detecting Long COVID and chronic fatigue conditions. Clinical validation studies now underway at Virax Biolabs.

#VRAX Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

www.stocktitan.net/news/VRAX/virax-biolabs-...

Cambodian man dies from bird flu A 28-year-old Cambodian man died from bird flu on Friday after eating sick chickens, the health ministry said.

28 yead old dies of bird flu. Is the bird flu stock rally over? #birdflu #nvax #mrna #vrax #cvac
medicalxpress.com/news/2025-01...

Virax Biolabs Advances T-Cell Platform with $7.3M War Chest, Expands European Distribution Network Virax strengthens its position with expanded EU partnerships, tripled lab capacity, and strong financials. Key clinical trial for T-cell dysfunction detection set for 2025 launch.

#VRAX Virax Biolabs' CEO James Foster Issues Letter to Shareholders

www.stocktitan.net/news/VRAX/virax-biolabs-...

Virax Biolabs Expands European Reach with Major Distribution Deal for ImmuneSelect Portfolio Virax Biolabs partners with Tebubio to distribute its ImmuneSelect research technology across Europe, boosting accessibility for life science institutions in key markets.

#VRAX Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

#StockMarket #investing #stocks

www.stocktitan.net/news/VRAX/virax-biolabs-...